Research progress on strategies to target intestinal microbiota to improve drug resistance in tumor immunotherapy
10.16438/j.0513-4870.2024-0740
- VernacularTitle:靶向肠道菌群改善肿瘤免疫治疗耐药策略的研究进展
- Author:
Hui-ling LI
1
;
Bi-qing LIU
2
;
Ying-nan FENG
1
;
Xin HU
3
;
Lan ZHANG
1
;
Xian-zhe DONG
1
Author Information
1. Department of Pharmacy, Xuanwu Hosptial, Capital Medical University, Beijing 100053, China
2. Department of Pharmacy, Children's Hospital Affiliated to Capital Institute of Pediatrics, Beijing 100020, China
3. Department of Pharmacy, Xuanwu Hosptial, Capital Medical University, Beijing 100053, China; College of Pharmacy, Zunyi Medical University, Zunyi 563000, China
- Publication Type:Research Article
- Keywords:
intestinal microbiota;
tumor immunotherapy;
targeted regulation;
improve drug resistance mechanism;
application challenge
- From:
Acta Pharmaceutica Sinica
2025;60(2):260-268
- CountryChina
- Language:Chinese
-
Abstract:
A growing body of research points out that gut microbiota plays a key role in tumor immunotherapy. By optimizing the composition of intestinal microbiota, it is possible to effectively improve immunotherapy resistance and enhance its therapeutic effect. This article comprehensively analyzes the mechanism of intestinal microbiota influencing tumor immunotherapy resistance, expounds the current strategies for targeted regulation of intestinal microbiota, such as traditional Chinese medicine and plant components, fecal microbiota transplantation, probiotics, prebiotics and dietary therapy, and explores the potential mechanisms of these strategies to improve patients' resistance to tumor immunotherapy. At the same time, the article also briefly discusses the prospects and challenges of targeting intestinal microbiota to improve tumor immunotherapy resistance, which provides a reference for related research to help the strategy research of reversing tumor immunotherapy resistance.
